Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Explore this paper's citation graph
Summary
Genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, are identified and validated the significance of these predictors in an independent cohort.
- Type
- article
- Published
- 2012-03-14
- Cited by
- 1,933
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2115707319
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2600699
Keywords
CEBPA, NPM1, Medicine, Daunorubicin, Internal medicine
References
- Resampling-Based Multiple Testing.
- Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
- The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate
- PHF6 mutations in adult acute myeloid leukemia
- IDH mutations in acute myeloid leukemia.
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
- Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
- Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
- Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
- High-dose daunorubicin in older patients with acute myeloid leukemia.
- Mutation in TET2 in myeloid cancers.
- Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
- CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
- TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Prognostically useful gene-expression profiles in acute myeloid leukemia.
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- DNMT3A Mutations in Acute Myeloid Leukemia
Cited by
- [Models of oncogenesis: an endless world?].
- CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
- A Novel HLA-A*0201 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target in Acute Myeloid Leukemia
- Acute myeloid leukaemia in adults.
- An evolutionary perspective on chronic myelomonocytic leukemia
- Acute myeloid leukemia with DNMT3A mutations
- Hematopoietic stem cell development: an epigenetic journey.
- Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
- Approach to patients with primary refractory acute myeloid leukemia
- A new path to leukemia with WIT.
- Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis.
- Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
- Allogeneic transplant for FLT3-ITD+ AML: room for improvement
- The Impact of DNA Methylation in Hematopoietic Malignancies
- Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches
- Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling
- Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
- Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia
- What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?
- Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Related papers
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Prognostic Significance of IDH1 and IDH2 mutations in Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia
- Additional mutations in IDH1/2‐mutated patients with acute myeloid leukemia
- Acute Myeloid Leukemia with IDH1 or IDH2 Mutations: Frequency and Clinicopathologic Features
- Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies.
- IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
- A Case Report of Concurrent IDH1 and NPM1 Mutations in a Novel t(X;2)(q28;p22) Translocation in Acute Myeloid Leukaemia without Maturation (AML-M1).
- The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia